Overview of antitumorigenic proteins with tPA-stimulating activity
Protein . | Effect on angiogenesis or tumor growth . | Stimulation of tPA-mediated plasminogen activation . |
|---|---|---|
| Endostatin | O'Reilly et al, 19974 | Reijerkerk et al, 200317 |
| Thrombospondin* | Volpert et al, 199862 | Silverstein et al, 1984, 1985, 198663-65 |
| Angiostatin† | O'Reilly et al, 19943 | Unknown |
| Denatured antithrombin III | O'Reilly et al, 19996 | Machovich and Owen, 199739 |
| Prothrombin fragments | Rhim et al, 19985 | Machovic et al, 199966 |
| βpep25 (Anginex) | Griffioen et al, 200167 | A.R., unpublished |
| Maspin | Zou et al, 199468 | Sheng et al, 199869 |
| Histidine-proline-rich glycoprotein | Juarez et al, 200270 | Silverstein et al, 198563 ; Borza and Morgan, 199771 |
| Fibrin(ogen) degradation products | AR unpublished and Brown et al, 20027 | Stewart et al, 199872 |
| Calreticulin (fragments), vasostatin | Pike et al, 199973 | Binds tPA. Allen and Bulleid, 199774 |
| Amphoterin‡ | Huttunen et al, 200255 | Parkinen and Rauvala, 199175 |
Protein . | Effect on angiogenesis or tumor growth . | Stimulation of tPA-mediated plasminogen activation . |
|---|---|---|
| Endostatin | O'Reilly et al, 19974 | Reijerkerk et al, 200317 |
| Thrombospondin* | Volpert et al, 199862 | Silverstein et al, 1984, 1985, 198663-65 |
| Angiostatin† | O'Reilly et al, 19943 | Unknown |
| Denatured antithrombin III | O'Reilly et al, 19996 | Machovich and Owen, 199739 |
| Prothrombin fragments | Rhim et al, 19985 | Machovic et al, 199966 |
| βpep25 (Anginex) | Griffioen et al, 200167 | A.R., unpublished |
| Maspin | Zou et al, 199468 | Sheng et al, 199869 |
| Histidine-proline-rich glycoprotein | Juarez et al, 200270 | Silverstein et al, 198563 ; Borza and Morgan, 199771 |
| Fibrin(ogen) degradation products | AR unpublished and Brown et al, 20027 | Stewart et al, 199872 |
| Calreticulin (fragments), vasostatin | Pike et al, 199973 | Binds tPA. Allen and Bulleid, 199774 |
| Amphoterin‡ | Huttunen et al, 200255 | Parkinen and Rauvala, 199175 |
Thrombospondin also binds the multiligand receptor CD36.56,76
Angiostatin that is tested in clinical trials is made in P pastoris. The original experiments, however, were performed with angiostatin prepared by proteolytic cleavage with elastase, followed by purification on a lysine-Sepharose column and subsequent dialysis against H2O.3 The latter method of purification leaves the possibility that fragments are present with amyloid properties. We, therefore, suggest that different forms of angiostatin may also yield differences in bioactivity.
Amphoterin also binds the multiligand receptor RAGE.55